Elan Pharmaceuticals, Inc.

Other

Wyeth

Michael S Dappen

Eugene D Thorsett

Michael A Pleiss

Francine S Grant

Christopher Michael Semko

Darren B Dressen

Andrei William Konradi

Louis John Lombardo

Martin Neitzel

Dimitrios Sarantakis

Louis Brogley

Michael Ye

Jon Eric Hawkinson

Ramesh Kasar

Sarah Bartulis

John Alan Tucker

Jenifer Lea Smith

Jennifer Marugg

Cynthia Y Robinson

Mohammed A Khan

Varghese John

Susan Ashwell

Anthony Frank Kreft

Reinhardt Bernhard Baudy

Minghua Sun

Simeon Bowers

Albert W Garofalo

Anh P Truong

Gary D Probst

Russell E Rydel

Xiaocong Michael Ye

Ryan C Holcomb

Raymond Ng

Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.

Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds

The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R, R, and Rare as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.

N-sulfonamido polycyclic pyrazolyl compounds

Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease.  In Formula (I), R, R, R, R, R, Rand Rare as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).

N-substituted benzene sulfonamides

Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.

Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists

Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R, R, R, R, R, Rand Rare as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).

Disclosed are sulfonylquinoxalone derivatives of the general formula: These compounds are useful as bradykinin antagonists.

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Compounds which inhibit leukocyte adhesion mediated by VLA-4

Disclosed are 1-sulfonylquioxalone acetamides and derivatives thereof. The compounds are exemplified by compounds of the formula: Such compounds, derivatives and related compounds are useful as bradykinin antagonists.

Sulfonylquinoxalone derivatives as bradykinin antagonists

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4

Substituted pyrimidine compositions and methods of use

Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4

Growing community of inventors

Redwood City, CA, United States of America

Michael S Dappen